<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">farmaec</journal-id><journal-title-group><journal-title xml:lang="en">FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology</journal-title><trans-title-group xml:lang="ru"><trans-title>ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2070-4909</issn><issn pub-type="epub">2070-4933</issn><publisher><publisher-name>IRBIS LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.17749/2070-4909.2017.10.1.066-071</article-id><article-id custom-type="elpub" pub-id-type="custom">farmaec-184</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Methodology</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Методология</subject></subj-group></article-categories><title-group><article-title>THE USE OF QALY AS AN INTEGRAL MEASURE OF EFFECTIVENESS IN THE EVALUATION OF MEDICAL TECHNOLOGIES</article-title><trans-title-group xml:lang="ru"><trans-title>МЕТОДЫ РАСЧЕТА QALY КАК ИНТЕГРАЛЬНОГО ПОКАЗАТЕЛЯ ЭФФЕКТИВНОСТИ В ПРОЦЕССЕ КОМПЛЕКСНОЙ ОЦЕНКИ ЛЕКАРСТВЕННЫХ ПРЕПАРАТОВ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мусина</surname><given-names>Н. З.</given-names></name><name name-style="western" xml:lang="en"><surname>Musina</surname><given-names>N. Z.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мусина Нурия Загитовна – кандидат фармацевтических наук, доцент кафедры фармакологии фармацевтического факультета ГБОУ ВПО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России; начальник отдела развития и внешних коммуникаций ФГБУ «Центр экспертизы и контроля качества медицинской помощи» Минздрава России</p></bio><bio xml:lang="en"><p>Musina Nuriya Zagitovna – PhD, lecturer of the Department of Pharmacology, Pharmaceutical Faculty First Moscow Medical Sechenov University; Chief of development and communications, Center of Healthcare Quality Assessment and Control, The Ministry of Health of Russian Federation. </p><p>Address: ul. Trubetskaya, 8-2, Moscow, Russia, 119048</p></bio><email xlink:type="simple">nuriyamusina@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Федяева</surname><given-names>В. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Fedyaeva</surname><given-names>V. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Федяева Влада Константиновна – научный сотрудник Центра оценки технологий в здравоохранении Института прикладных экономических исследований РАНХиГС при Президенте РФ; младший научный сотрудник Центра финансов здравоохранения НИФИ Минфина РФ</p></bio><bio xml:lang="en"><p>Fedyaeva Vlada Konstantinovna – Researcher at the Center for Health Technology Assessment of the Russian Presidential Academy of National Economy and Public Administration; junior researcher at the Health Care Finance Center of the Research Financial Institute of the Ministry of Finance of the Russian Federation</p></bio><email xlink:type="simple">vlada.fedyaeva@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ГБОУ ВПО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России;&#13;
ФГБУ Центр экспертизы и контроля качества медицинской помощи Министерства здравоохранения РФ<country>Россия</country></aff><aff xml:lang="en">First Moscow State Medical Sechenov University of the Ministry of Health Russian Federation;&#13;
Center of Expertise and Quality Control of Medical Care, Ministry of Health of the Russian Federation<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">ФГБУ Центр экспертизы и контроля качества медицинской помощи Министерства здравоохранения РФ; &#13;
ФГБУ Научно-исследовательский финансовый институт Минфина РФ<country>Россия</country></aff><aff xml:lang="en">Center of Expertise and Quality Control of Medical Care, Ministry of Health of the Russian Federation;&#13;
Scientific and Research Financial Institute, Ministry of Finances<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>23</day><month>05</month><year>2017</year></pub-date><volume>10</volume><issue>1</issue><fpage>66</fpage><lpage>71</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Musina N.Z., Fedyaeva V.K., 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="ru">Мусина Н.З., Федяева В.К.</copyright-holder><copyright-holder xml:lang="en">Musina N.Z., Fedyaeva V.K.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmacoeconomics.ru/jour/article/view/184">https://www.pharmacoeconomics.ru/jour/article/view/184</self-uri><abstract><p>This report addresses the ways of calculating QALY (Quality-adjusted life-year). OutsideRussia, a standardized methodology to calculate QALY is in use; such an approach makes it possible to apply this universal criterion of effectiveness to the evaluation of new health technologies. Its versatility enables better decision-making on financing the medical treatment within a limited budget. With this algorithm, the financial resources are allocated in such a way as to maximize the levels of QALY. InRussiato date, the use of QALY as a measure of drug effectiveness is not yet possible because of the lack of standardized calculating methods, as well as the absence of uniform tariffs for assessing the medical status of the patient in terms of health utility. Here, we present a number of methods for estimating the health utility, which are used to calculate the QALY, and describe advantages and disadvantages of these methods. </p></abstract><trans-abstract xml:lang="ru"><p>В статье описаны основные подходы к вычислению QALY. В зарубежных странах разработана и используется стандартизованная методика расчета QALY, позволяющая применять данный показатель как универсальный критерий эффективности при проведении оценки технологий здравоохранения. Его универсальность позволяет принимать решения о финансировании медицинских технологий для лечения различных заболеваний в рамках ограниченного бюджета. При этом финансовые ресурсы распределяются таким образом, чтобы максимизировать прирост QALY. В России на сегодняшний день использование QALY как критерия эффективности при проведении комплексной оценки лекарственных препаратов не представляется возможным ввиду отсутствия стандартизованной методики расчета, а также отсутствия единых тарифов для перевода профилей состояний здоровья в полезность. Приведены основные методы расчета полезностей состояний здоровья, необходимых для вычисления QALY, описаны основные достоинства и недостатки существующих методов. </p></trans-abstract><kwd-group xml:lang="ru"><kwd>годы качественной жизни</kwd><kwd>QALY</kwd><kwd>качество жизни</kwd><kwd>полезность</kwd><kwd>комплексная оценка</kwd><kwd>оценка технологий здравоохранения</kwd></kwd-group><kwd-group xml:lang="en"><kwd>quality-adjusted life-year</kwd><kwd>QALY</kwd><kwd>quality of life</kwd><kwd>utility</kwd><kwd>complex approach</kwd><kwd>medical technology assessment</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Федеральный закон от 22.12.2014 г. № 429-ФЗ «О внесении изменений в Федеральный закон «Об обращении лекарственных средств».</mixed-citation><mixed-citation xml:lang="en">Federal law dated 22.12.2014, No. 429-FZ “On amendments to the Federal law “On circulation of medicines” [Federal’nyi zakon ot 22.12.2014 g. № 429-FZ «O vnesenii izmenenii v Federal’nyi zakon «Ob obrashchenii lekarstvennykh sredstv» (in Russian)].</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Авксентьева М.В., Омельяновский В.В. Международный опыт оценки технологий в здравоохранении. Рецепт. 2010; 6: 40-51.</mixed-citation><mixed-citation xml:lang="en">Avksent’eva M.V., Omel’yanovskii V.V. Retsept. 2010; 6: 40-51.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Постановление Правительства РФ от 28.08.2014 N 871 «Об утверждении Правил формирования перечней лекарственных препаратов для медицинского применения и минимального ассортимента лекарственных препаратов, необходимых для оказания медицинской помощи».</mixed-citation><mixed-citation xml:lang="en">he decree of the RF Government dated 28.08.2014 N 871 “On approval of Rules of forming of lists of medicinal preparations for medical application and the minimum assortment of medicinal preparations necessary for rendering of medical care” [Postanovlenie Pravitel’stva RF ot 28.08.2014 N 871 «Ob utverzhdenii Pravil formirovaniya perechnei lekarstvennykh preparatov dlya meditsinskogo primeneniya i minimal’nogo assortimenta lekarstvennykh preparatov, neobkhodimykh dlya okazaniya meditsinskoi pomoshchi» (in Russian)]</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Реброва О.Ю. Описание статистического анализа данных в оригинальных статьях. Типичные ошибки. Медицинские технологии. Оценка и выбор. 2011; 4.</mixed-citation><mixed-citation xml:lang="en">Rebrova O.Yu. Meditsinskie tekhnologii. Otsenka i vybor. 2011; 4.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Drummond M. F., Sculpher M. J., Torrance G.W., O’Brien B. J., Stoddart G. L. Methods for the economic evaluation of health care programmes. Oxford, USA, 2005.</mixed-citation><mixed-citation xml:lang="en">Drummond M. F., Sculpher M. J., Torrance G.W., O’Brien B. J., Stoddart G. L. Methods for the economic evaluation of health care programmes. Oxford, USA, 2005.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Мусина Н.З. Фармацевтическая информация. М. 2012; 136с.</mixed-citation><mixed-citation xml:lang="en">Musina N.Z. Pharmaceutical information [Farmatsevticheskaya informatsiya (in Russian)]. Moscow. 2012; 136 s.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">NICE, “Guide to the methods of technology appr appraisal 2013” 2013. URL: https://www.nice.org.uk/process/pmg9/resources/guideto-the-methods-of-technology-appraisal-2013-pdf-2007975843781/. Дата обращения: 11.01.2017.</mixed-citation><mixed-citation xml:lang="en">NICE, “Guide to the methods of technology appr appraisal 2013” 2013. URL: https://www.nice.org.uk/process/pmg9/resources/guideto-the-methods-of-technology-appraisal-2013-pdf-2007975843781/. Accessed: 11.01.2017.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Опросник EQ-5D-3L. URL: http://www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Folders_Flyers/EQ-5D-3L_UserGuide_2015.pdf. Дата обращения: 11.01.2017.</mixed-citation><mixed-citation xml:lang="en">The questionnaire EQ-5D-3L. URL: http://www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Folders_Flyers/EQ-5D-3L_UserGuide_2015.pdf. Accessed: 11.01.2017.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Опросник EQ-5D-5L URL: http://www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Folders_Flyers/EQ-5D-5L_UserGuide_2015.pdf. Дата обращения: 11.01.2017.</mixed-citation><mixed-citation xml:lang="en">The questionnaire EQ-5D-3L. URL: http://www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Folders_Flyers/EQ-5D-5L_UserGuide_2015.pdf. Accessed: 11.01.2017.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Dolan P. Modeling valuations for EuroQol health states. Medical Care. 1997; 35 (11): 1095–1108.</mixed-citation><mixed-citation xml:lang="en">Dolan P. Modeling valuations for EuroQol health states. Medical Care. 1997; 35 (11): 1095–1108.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Guide to the methods of technology appraisal 2013 URL: http://publications.nice.org.uk/pmg9. Дата обращения: 11.01.2017.</mixed-citation><mixed-citation xml:lang="en">Guide to the methods of technology appraisal 2013 URL: http://publications.nice.org.uk/pmg9. Accessed: 11.01.2017.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Longworth L., Rowen D. Mapping to obtain EQ-5D utility values for use in NICE health technology assessments. Value in Health. 2013; 16 (1): 202-210.</mixed-citation><mixed-citation xml:lang="en">Longworth L., Rowen D. Mapping to obtain EQ-5D utility values for use in NICE health technology assessments. Value in Health. 2013; 16 (1): 202-210.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Brazier J., Ratcliffe J., Salomon J.A., Tsuchiya A. Measuring and valuing health benefits for economic evaluation. Oxford, USA, 2007</mixed-citation><mixed-citation xml:lang="en">Brazier J., Ratcliffe J., Salomon J.A., Tsuchiya A. Measuring and valuing health benefits for economic evaluation. Oxford, USA, 2007.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
